Thymopentin

Thymopentin
Clinical data
Other names	L-arginyl-L-lysyl-L-α-aspartyl-L-valyl-L-tyrosine
ATC code	L03AX09 (WHO) ;
Identifiers
	IUPAC name (3S)-3-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid;
CAS Number	69558-55-0 ;
PubChem CID	451417;
ChemSpider	397640 ;
UNII	O3Y80ZF13F;
KEGG	D06117 ;
ChEMBL	ChEMBL156025 ;
NIAID ChemDB	000127;
CompTox Dashboard (EPA)	DTXSID9046609 ;
ECHA InfoCard	100.242.320
Chemical and physical data
Formula	C30H49N9O9
Molar mass	679.776 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccc(O)cc1)C(C)C)CC(=O)O)CCCCN)[C@@H](N)CCC/N=C(\N)N;
	InChI InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24-/m0/s1 ; Key:PSWFFKRAVBDQEG-YGQNSOCVSA-N ;
	(verify)

Thymopentin is an immunostimulant. As such, it has been used in several clinical studies in the early years of the AIDS pandemic (from 1983 to 1985). Thymopentin helped to improve immunological condition in several patients for a brief time under specific treatments.^[1]^[2]^[3]

It interacts with T cells.^[4]

It is a thymic polypeptide.^[5]

^ Mascart-Lemone F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J (1983). "Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients". Lancet. 322 (8352): 735–736. doi:10.1016/S0140-6736(83)92271-7. PMID 6193382. S2CID 519367.
^ Clumeck N, Van de Perre P, Mascart-Lemone F, Cran S, Bolla K, Duchateau J (1984). "Preliminary results on clinical and immunological effects of thymopentin in AIDS". Int J Clin Pharmacol Res. 4 (6): 459–463. PMID 6398315.
^ Clumeck N, Cran S, Van de Perre P, Mascart-Lemone F, Duchateau J, Bolla K (1985). "Thymopentin treatment in AIDS and pre-AIDS patients". Surv Immunol Res. 4 (1): supp1 58–62. doi:10.1007/BF02919057. PMID 3898293. S2CID 36555170.
^ Liu Z, Zheng X, Wang J, Wang E (2007). Egli M (ed.). "Molecular analysis of thymopentin binding to HLA-DR molecules". PLOS ONE. 2 (12): e1348. Bibcode:2007PLoSO...2.1348L. doi:10.1371/journal.pone.0001348. PMC 2137936. PMID 18159232.
^ Peng Y, Chen Z, Yu W, et al. (July 2008). "Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells". Cell Biology International. 32 (10): 1265–71. doi:10.1016/j.cellbi.2008.07.011. PMID 18692582. S2CID 24144448.

[pmid6193382-1] Mascart-Lemone F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J (1983). "Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients". Lancet. 322 (8352): 735–736. doi:10.1016/S0140-6736(83)92271-7. PMID 6193382. S2CID 519367.

[pmid6398315-2] Clumeck N, Van de Perre P, Mascart-Lemone F, Cran S, Bolla K, Duchateau J (1984). "Preliminary results on clinical and immunological effects of thymopentin in AIDS". Int J Clin Pharmacol Res. 4 (6): 459–463. PMID 6398315.

[pmid3898293-3] Clumeck N, Cran S, Van de Perre P, Mascart-Lemone F, Duchateau J, Bolla K (1985). "Thymopentin treatment in AIDS and pre-AIDS patients". Surv Immunol Res. 4 (1): supp1 58–62. doi:10.1007/BF02919057. PMID 3898293. S2CID 36555170.

[pmid18159232-4] Liu Z, Zheng X, Wang J, Wang E (2007). Egli M (ed.). "Molecular analysis of thymopentin binding to HLA-DR molecules". PLOS ONE. 2 (12): e1348. Bibcode:2007PLoSO...2.1348L. doi:10.1371/journal.pone.0001348. PMC 2137936. PMID 18159232.

[pmid18692582-5] Peng Y, Chen Z, Yu W, et al. (July 2008). "Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells". Cell Biology International. 32 (10): 1265–71. doi:10.1016/j.cellbi.2008.07.011. PMID 18692582. S2CID 24144448.

[1]

[2]

[3]

[4]

[5]